9 analysts have expressed a variety of opinions on Phreesia PHR over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 2 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Phreesia, revealing an average target of $31.33, a high estimate of $35.00, and a low estimate of $29.00. Marking an increase of 5.59%, the current average surpasses the previous average price target of $29.67.
Understanding Analyst Ratings: A Comprehensive Breakdown
A clear picture of Phreesia's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jessica Tassan | Piper Sandler | Raises | Overweight | $33.00 | $31.00 |
| Daniel Grosslight | Citigroup | Raises | Buy | $35.00 | $31.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $29.00 | $29.00 |
| Scott Schoenhaus | Keybanc | Raises | Overweight | $30.00 | $28.00 |
| Sean Dodge | RBC Capital | Raises | Outperform | $32.00 | $24.00 |
| Jailendra Singh | Truist Securities | Raises | Buy | $34.00 | $31.00 |
| Joseph Vruwink | Baird | Lowers | Outperform | $30.00 | $34.00 |
| Aaron Kimson | JMP Securities | Maintains | Market Outperform | $30.00 | $30.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $29.00 | $29.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Phreesia. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Phreesia compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Phreesia's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Phreesia's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Phreesia analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Phreesia Better
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
Phreesia's Financial Performance
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Phreesia showcased positive performance, achieving a revenue growth rate of 16.57% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -13.49%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -5.69%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Phreesia's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.9%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Phreesia's debt-to-equity ratio is below the industry average. With a ratio of 0.08, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
